Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Baxter

Revenues up 16% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter
 
2Q Revenues: $4.3 billion (+16%)

2Q Earnings: $520 million (-12%)

YTD Revenues: $8.2 billion (+15%)

YTD Earnings: $1.1 billion (-6%)

Comments: BioScience revenues were up 7% to $1.8 billion in the quarter, led by double-digit growth of ADVATE and albumin, as well as increased global demand for GAMMAGARD LIQUID, biosurgery products and select vaccines. Medical Product sales were $2.5 billion, up 24%, driven primarily by strong sales of injectable drugs, anesthetics and nutritional therapies, as well as gains in peritoneal dialysis patients, particularly in the U.S. and emerging markets. Results include after-tax special items totaling $172 million, primarily for amortization and costs associated with revenue and product development milestones, remediation efforts for the in-progress SPECTRUM Infusion Pump recall, integration of Gambro AB, and Baxter’s planned separation into two independent healthcare companies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters